NewsRoom Articles - Page 53 of 207

ThursdaySep 28, 2023 2:21 pm

Eliminating Barriers Surrounding Solid Tumors Allows T Cells to Kill Cancerous Cells

A recent University of Pennsylvania study has found that getting rid of the barriers surrounding solid tumors allows T cells to kill cancer cells more effectively. The research indicates that it is possible to make immunotherapies more effective at treating solid tumors such as lung cancer and pancreatic cancer. Immunotherapy is a relatively new type of cancer treatment that involves “training” the immune system to make it more effective at identifying and killing cancerous cells in the body. However, while this treatment has proven to be relatively effective at treating blood cancers, immunotherapies rarely have an impact on solid cancers.…

ThursdaySep 28, 2023 9:45 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) Presents Achievements, Goals at H.C. Wainwright 25th Annual Global Investment Conference in New York City

RVL Pharmaceuticals CEO Brian Markison participated in a fireside chat and hosted one-on-one investor meetings during the conference The company's primary focus is the commercialization of UPNEEQ(R), which is available by prescription for treating acquired blepharoptosis or low-lying eyelids in adults The global medical aesthetics market was estimated at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027, growing at a CAGR of 11% RVL Pharmaceuticals markets UPNEEQ(R) to HCPs and plans to launch a direct-to-consumer campaign later this year RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization and development of products…

ThursdaySep 28, 2023 9:00 am

Clene Inc. (NASDAQ: CLNN) Is ‘One to Watch’

In June 2023, The Lancet’s eClinicalMedicine journal published combined detailed analyses of Clene’s Phase 2 RESCUE-ALS study and its open-label extension trial In June 2023, Clene announced the closing of a $40 million underwritten public offering with potentially up to an additional $130 million from future warrant exercises As of January 2023, Clene had more than 150 issued patents worldwide and approximately 20 patents pending worldwide on top of many trade secrets Clene owns worldwide rights to commercialize its therapeutics but is looking for a partner to advance the MS indication Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on…

WednesdaySep 27, 2023 11:43 am

How to Maximize ROI from an eCommerce Advertising Budget

With Americans spending hundreds of billions of dollars on online purchases every year, e-commerce is one of the largest platforms for trade in the country. It allows companies to significantly broaden their potential customer base and provides varied and affordable means of marketing and advertising. With an estimated 2.5 million online retailers in the United States alone and 9.1 million on the entire globe, a proper marketing and advertising strategy will be key to attracting a sufficient customer base and building a respectable brand. Maximizing ROI on advertising will allow you to bring in as much value as possible from…

WednesdaySep 27, 2023 9:45 am

Longeveron Inc. (NASDAQ: LGVN) Eyeing Global HLHS, in addition to Alzheimer’s Disease, and Aging-Related Frailty Treatment Markets with Lomecel-B(TM), its Lead Investigational Product

Longeveron’s study ELPIS I demonstrated 100% survival and heart transplant-free for up to 5 years of age All ten patients enrolled in the study were monitored for at least 3.5 years after treatment with Lomecel-B(TM), the company’s lead investigational product Longeveron’s study results show Lomecel-B(TM)’s potential, not just for the potential treatment of HLHS but also for Alzheimer’s disease and Aging-related Frailty Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, recently posted promising results from its ELPIS I clinical trial. Of note was data that showed that 100% of the ten patients who…

TuesdaySep 26, 2023 2:33 pm

Surgical Robot Prototype Could Ease Pediatric Brain Cancer Surgery

Researchers from Boston Children’s Hospital say they have created a prototype surgical tool that can allow surgeons to remove pediatric brain tumors safely and in a less invasive manner. The surgical robot uses hollow, nitinol robot arms to give surgeons the ability to switch tools during tumor resections and could also have applications for neurosurgery in adults and other surgical procedures. Study coauthor and Boston Children’s Hospital chief of pediatric cardiac bioengineering Pierre DuPont said the idea for the project goes back to 2016 when he had conversations with Dr. Jim Drake, the chief of neurosurgery at Toronto-based SickKids. DuPont…

TuesdaySep 26, 2023 9:00 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) Looking to Capitalize on UPNEEQ’s Significant Potential

UPNEEQ(R) is the first FDA-approved non-surgical treatment option for acquired blepharoptosis (ptosis), or low-lying eyelid Clinical studies have shown an average one-millimeter lift of the upper eyelid, with results in as little as five minutes post-dose UPNEEQ(R) is available through RVL Pharmaceuticals’ dedicated e-commerce platform, Elevate, which supports subscription ordering by HCPs and RVL Pharmacy patients RVL is poised to be an integral player in the global medical aesthetic market, which is estimated to reach $18 billion by 2027 RVL Pharmaceuticals (NASDAQ: RVLP), is a specialty pharmaceutical company focusing on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for…

MondaySep 25, 2023 1:17 pm

Inverse Vaccines Show Promise Against Autoimmunity

University of Chicago Pritzker School of Molecular Engineering (PME) researchers have developed a new vaccine that has completely reversed autoimmune disorders in laboratory settings. This “inverse vaccine” works by wiping out the immune system’s memory of a perceived irritant rather than suppressing the immune system to limit autoimmunity symptoms. The immune system is essentially a battle-ready system of defenses ready to attack and destroy any threats at the drop of a hat. In some people, the immune system is overly sensitive and will react aggressively after mistaking harmless substances such as proteins, pollen and healthy tissues, for threats. This results…

MondaySep 25, 2023 10:30 am

Trial Enrollment Growth Supports Plans of CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Complete Enrollment for Important Brain Cancer Drug Study

CNS Pharmaceuticals is conducting a global clinical trial to evaluate its flagship drug candidate for treating glioblastoma, a deadly brain cancer CNS has enrolled 200 of its planned 243 patients for its clinical trial roster, and anticipates filling out the remainder of patients by year’s end The company is also preparing the interim study analysis for release by year’s end, now that more than 50 percent of the planned patient roster has reached a point necessary for effective comparison of performance of the flagship drug, Berubicin, to that of a standard of care chemotherapy agent The company has stated that…

FridaySep 22, 2023 12:29 pm

Why Colon Cancer Is Largely Unresponsive to Immunotherapy

Colorectal cancer is the third-most common type of cancer among adults in the United States, affecting an estimated 106,970 people in 2023 and predicted to take more than 50,000 lives this year. Treatment often involves surgery to remove as much of the tumor as possible, followed by chemotherapy and radiation therapy to kill off any remaining tumor cells. Recent research published in the “Nature Genetics” journal has shed new light on why immunotherapy, a relatively new type of cancer treatment that uses a patient’s own immune system to kill cancer cells, isn’t as effective against colon cancers. Researchers studied the…